BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ligufalimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ligufalimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05227664-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ligufalimab: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Ligufalimab\, phase 2.\nStudy: A Study of AK117/AK112 in Metast
 atic Triple-Negative Breast Cancer\nEstimated primary completion: 30 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ligufalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052
 27664
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05229497-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ligufalimab: Phase 1/2 readout est. (NCT05229497)
DESCRIPTION:Ligufalimab\, phase 1/2.\nStudy: A Phase Ib/II Study of AK112 i
 n Combination With AK117 in Advanced Malignant Tumors\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ligufalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05229497
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ligufalimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ligufalimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ligufalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ligufalimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ligufalimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ligufalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642792-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ligufalimab: Phase 1/2 readout est. (NCT06642792)
DESCRIPTION:Ligufalimab\, phase 1/2.\nStudy: A Study of AK129 With or Witho
 ut AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma\nEstimated primary 
 completion: November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ligufalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06642792
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245446-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ligufalimab: Phase 2 readout est. (NCT07245446)
DESCRIPTION:Ligufalimab\, phase 2.\nStudy: A Study of Ivonescimab in First-
 Line ES-SCLC\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ligufalimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07245446
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789848-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ligufalimab: Phase 2 readout est. (NCT06789848)
DESCRIPTION:Ligufalimab\, phase 2.\nStudy: Ligufalimab and Cadonilimab in A
 dvanced Liver Cancers\nEstimated primary completion: 31 May 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ligufalimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06789848
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264075-2833@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Ligufalimab: Phase 3 readout est. (NCT07264075)
DESCRIPTION:Ligufalimab\, phase 3.\nStudy: Study Comparing Ivonescimab Alon
 e or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for 
 the Treatment of SCCHN\nEstimated primary completion: May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ligufalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07264075
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
